Table 1

Apo2.7 immunohistochemical staining and image analysis of tumor from patients immunized with 105AD7 or matched control tumors

PatientAgea (yr)GenderOperationbSitecStagedPixel countse
Immunized
179F14SigmoidB395, 249, and 368
351, 412, and 565
276M14SigmoidA161, 192, and 265
349, 342, and 324
375M26RectumA175, 241, and 286
456M9RectumB766, 693, and 566
570M13RectumB  64, 87, and 60 
662F20RectumC206, 191, and 182
90, 196, and 82
787M20CecumB632, 523, and 451
882M11CecumC292, 289, and 222
Controls
175FSigmoidB217, 173, and 59 
167, 188, and 177
279MSigmoidA262, 155, and 170
182, 210, and 163
370MRectumA 152, 96, and 156
460MRectumB214, 262, and 222
573MRectumB53, 62, and 81
665FRectumC299, 221, and 300
363, 356, and 204
781MCecumB165, 177, and 176
875MCecumC  87, 94, and 104
  • a Age of patient at trial entry.

  • b Time in days between immunization and tumor resection.

  • c Site of primary tumor.

  • d Dukes’ stage.

  • e Mean pixel count for five areas of a tumor section stained with Apo2.7. The same regions of immunized and control tumors were paired and analyzed for significance by a two-tailed Wilcoxon signed rank test. Significantly (P < 0.005) more infiltration was seen in immunized tumors than in control tumors.